Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2024 Apr 1

PMID 38561367

Authors

Shuaixi Yang

Yuhang Wang

Jiachi Jia

Yingshuai Fang

Yabing Yang

Weitang Yuan

Junhong Hu

Affiliations

Soon will be listed here.

Abstract

Macrophages, as pivotal cells within the tumour microenvironment, significantly influence the impact of and reactions to treatments for solid tumours. The rapid evolution of bioengineering technology has revealed the vast potential of engineered macrophages in immunotherapy, disease diagnosis, and tissue engineering. Given this landscape, the goal of harnessing and innovating macrophages as a novel strategy for solid tumour immunotherapy cannot be overstated. The diverse strategies for engineered macrophages in the realm of cancer immunotherapy, encompassing macrophage drug delivery systems, chimeric antigen receptor macrophage therapy, and synergistic treatment approaches involving bacterial outer membrane vesicles and macrophages, are meticulously examined in this review. These methodologies are designed to enhance the therapeutic efficacy of macrophages against solid tumours, particularly those that are drug-resistant and metastatic. Collectively, these immunotherapies are poised to supplement and refine current solid tumour treatment paradigms, thus heralding a new frontier in the fight against malignant tumours.

Citing Articles

Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?.

Bhatia D, Dolcetti R, Mazzieri R J Exp Clin Cancer Res. 2025; 44(1):98.

PMID: 40089746 DOI: 10.1186/s13046-025-03359-x.

Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy.

Kuhl G, Tangney M Cancers (Basel). 2025; 17(5).

PMID: 40075571 PMC: 11899205. DOI: 10.3390/cancers17050723.

An adoptive cell therapy with TREM2-overexpressing macrophages mitigates the transition from acute kidney injury to chronic kidney disease.

Zhang Y, Liu Y, Luo S, Liang H, Guo C, Du Y Clin Transl Med. 2025; 15(3):e70252.

PMID: 40000418 PMC: 11859120. DOI: 10.1002/ctm2.70252.

Chimeric Antigen Receptor Cell Therapy: Empowering Treatment Strategies for Solid Tumors.

Jaing T, Hsiao Y, Wang Y Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996811 PMC: 11854309. DOI: 10.3390/cimb47020090.

How to Use Macrophages Against Cancer.

Kuznicki J, Janicka N, Bialynicka-Birula B, Kuznicki W, Chorazyczewska H, Deszcz I Cells. 2024; 13(23).

PMID: 39682696 PMC: 11639767. DOI: 10.3390/cells13231948.

References

Chen C, Jing W, Chen Y, Wang G, Abdalla M, Gao L . Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci Transl Med. 2022; 14(656):eabn1128. DOI: 10.1126/scitranslmed.abn1128. View

Ikehara Y, Niwa T, Biao L, Ikehara S, Ohashi N, Kobayashi T . A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res. 2006; 66(17):8740-8. DOI: 10.1158/0008-5472.CAN-06-0470. View

Choi J, Kim H, Ju E, Jung J, Park J, Chung H . Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials. 2012; 33(16):4195-203. DOI: 10.1016/j.biomaterials.2012.02.022. View

Roszer T . Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms. Mediators Inflamm. 2015; 2015:816460. PMC: 4452191. DOI: 10.1155/2015/816460. View

Baslan T, Hicks J . Unravelling biology and shifting paradigms in cancer with single-cell sequencing. Nat Rev Cancer. 2017; 17(9):557-569. DOI: 10.1038/nrc.2017.58. View

Dong X, Fan J, Xie W, Wu X, Wei J, He Z . Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer. Br J Cancer. 2023; 129(3):551-562. PMC: 10403530. DOI: 10.1038/s41416-023-02319-6. View

Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z . Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B. 2021; 11(4):941-960. PMC: 8105778. DOI: 10.1016/j.apsb.2020.12.018. View

Gunassekaran G, Vadevoo S, Baek M, Lee B . M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021; 278:121137. DOI: 10.1016/j.biomaterials.2021.121137. View

Li Y, Cong Z, Xie L, Tang S, Ren C, Peng X . Magnetically Powered Immunogenic Macrophage Microrobots for Targeted Multimodal Cancer Therapy. Small. 2023; 19(42):e2301489. DOI: 10.1002/smll.202301489. View

10.

Jiang T, Shen S, Wang T, Li M, He B, Mo R . A Substrate-Selective Enzyme-Catalysis Assembly Strategy for Oligopeptide Hydrogel-Assisted Combinatorial Protein Delivery. Nano Lett. 2017; 17(12):7447-7454. DOI: 10.1021/acs.nanolett.7b03371. View

11.

DAloia M, Zizzari I, Sacchetti B, Pierelli L, Alimandi M . CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018; 9(3):282. PMC: 5833816. DOI: 10.1038/s41419-018-0278-6. View

12.

Jin M, Jin W . The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020; 5(1):166. PMC: 7447642. DOI: 10.1038/s41392-020-00280-x. View

13.

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

14.

Boutilier A, Elsawa S . Macrophage Polarization States in the Tumor Microenvironment. Int J Mol Sci. 2021; 22(13). PMC: 8268869. DOI: 10.3390/ijms22136995. View

15.

Kang M, Lee S, Kwon M, Byun J, Kim D, Kim C . Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy. Adv Mater. 2021; 33(43):e2103258. DOI: 10.1002/adma.202103258. View

16.

Chen M, Liu T, Chen Y, Chen M . Combining Augmented Radiotherapy and Immunotherapy through a Nano-Gold and Bacterial Outer-Membrane Vesicle Complex for the Treatment of Glioblastoma. Nanomaterials (Basel). 2021; 11(7). PMC: 8306693. DOI: 10.3390/nano11071661. View

17.

Zhuang W, Wang Y, Nie W, Lei Y, Liang C, He J . Bacterial outer membrane vesicle based versatile nanosystem boosts the efferocytosis blockade triggered tumor-specific immunity. Nat Commun. 2023; 14(1):1675. PMC: 10039929. DOI: 10.1038/s41467-023-37369-0. View

18.

Facklam A, Volpatti L, Anderson D . Biomaterials for Personalized Cell Therapy. Adv Mater. 2019; 32(13):e1902005. DOI: 10.1002/adma.201902005. View

19.

Elhanani O, Ben-Uri R, Keren L . Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023; 41(3):404-420. DOI: 10.1016/j.ccell.2023.01.010. View

20.

Locati M, Curtale G, Mantovani A . Diversity, Mechanisms, and Significance of Macrophage Plasticity. Annu Rev Pathol. 2019; 15:123-147. PMC: 7176483. DOI: 10.1146/annurev-pathmechdis-012418-012718. View